SWShanshan Wei

Shanshan Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shanshan Wei has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Boquan Xiong

    Department of Anesthesiology Liuzhou Municipal Liutie Central Hospital Liuzhou Guangxi China

    1 shared publication
  • Chendong Ma

    Department of Anesthesiology Liuzhou Municipal Liutie Central Hospital Liuzhou Guangxi China

    1 shared publication
  • Huageng Huang

    Department of Anesthesiology The Third Affiliated Hospital of Guangxi Medical University Nanning Guangxi China

    1 shared publication
  • Jun Jiang

    Department of Anesthesiology Liuzhou Municipal Liutie Central Hospital Liuzhou Guangxi China

    1 shared publication
  • Kejian Lu

    Department of Anesthesiology The Third Affiliated Hospital of Guangxi Medical University Nanning Guangxi China

    1 shared publication
  • Liuhui Fu

    Department of Anesthesiology Liuzhou Municipal Liutie Central Hospital Liuzhou Guangxi China

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Remimazolam versus propofol for deep sedation/anaesthesia in upper gastrointestinal endoscopy in elderly patients: A multicenter, randomized controlled trial

    by Kejian Lu, Shanshan Wei, Wenwen Ling, Yanxia Wei, Xuelian Ran, Huageng Huang, Meixu Wang, Ning Wei, Yanying Liao, Zailing Qin, et al.

    Propofol is the most commonly used sedative in gastrointestinal endoscopic procedures, but is associated with cardiorespiratory suppression, particularly in elderly patients. Remimazolam is a new short‐acting GABA(A) receptor agonist with minimal impact on cardiorespiratory suppression, and may be a viable alternative in elderly patients undergoing endoscopic procedures. This multicenter, randomized controlled trial was conducted between September 2020 and September 2021. Elderly patients (65–85 years of age) scheduled to undergo upper gastrointestinal endoscopy were randomized in 1:1 ratio to receive remimazolam tosilate (300 mg/h) or propofol (3 g/h) in addition to 50‐μg fentanyl, until the Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S) reached ≤1. MOAA/S was maintained at 0 or 1 throughout the procedure using 2.5 mg remimazolam or 0.5 mg/kg propofol boluses in the two groups, respectively. The primary outcome was the rate of hypotension (defined as systolic blood pressure at ≤90 mmHg or > 30% decline vs. the baseline). Bradycardia was defined as heart rate ≤50 per minute; respiratory depression was defined as respiratory rate 2 < 90%. A total of 400 patients (161 men and 239 women; 70.4 ± 4.6 years of age) were enrolled (200 patients per group). Average body mass index was 22.2 ± 2.4 kg/m2. The rate of hypotension was 36.5% in the remimazolam group and 69.6% in the propofol group (p < 0.001). The remimazolam group also had a lower rate of bradycardia (1.5% vs. 8.5%, p < 0.001), respiratory depression (4.5% vs. 10.0%, p < 0.05) and pain at the injection site (0% vs. 12.0%, p < 0.001). Remimazolam was associated with a lower rate of hypotension in elderly patients undergoing upper gastrointestinal endoscopy under deep sedation/anaesthesia than propofol.